摘要
目的探讨钙拮抗剂抑制肝纤维化改善门脉高动力循环的作用机制。方法分三组测定肝组织中一氧化氮合酶 (NOS)活性和血清中一氧化氮 (NO) ;观察门静脉血流量 (PVF)、门静脉压力(PVP)、门静脉阻力 (PVR)及肝脏病理学改变。结果钙拮抗剂汉防己甲素显著抑制NOS活性和NO生成 ,明显降低PVP和PVF ,病理切片显示汉防己甲素明显防止肝细胞坏死 ,阻止肝纤维化发展。
Objective To investigate the mechanism of calciam antagonists that inhibited hepatic fibrosis and to improve the portal venous high dynamic circulation Methods The study was divided into three group the Nos enzymatic activity in hepatic tissue and NO activity in serum were determined.The portal venous flow (PVF), portal venous pressure (PVP),portal venous resistance (PVR) and pathologic examination of liver from three groups were tested.Results Tetrandrine of calcium antagonists was significantly to inhibite the Nos enxymatic activity and NO production and to decrease PVP and PVF. Tetrandrine can prevent the necrosis of hepatic cells and delaying the development of hepatic fibrosis.Conclusion The main preventing mechanism of cirrhosis and portal hypertension was inhibiting the Nos enzymatic activity and No production by calcium antagonists.
出处
《贵州医药》
CAS
2000年第1期8-10,共3页
Guizhou Medical Journal
关键词
钙拮抗剂
肝硬化
门脉高压症
一氧化氮合酶
Calcium Antagonist Cirrhosis Portal hypertension Nitric oxide synthase
